USC Donations Drop $100 Million after Puliafito Scandal, Report Says

February 9, 2018: By Joan McKenna

The University of Southern California saw a $100 million drop in contributions in the last half of 2017 in the wake of a scandal involving former ophthalmologist Carmen Puliafito, according to a story published Feb. 7 by The Los Angeles Times.

Donations dropped $45 million, or 55 percent, within USC’s Keck School of Medicine, where Puliafito served as dean from August 2007 to March 2016.

The decline in support followed publication of a Los Angeles Times story in July 2017 alleging that Puliafito used methamphetamine and other drugs and kept company with prostitutes and drug users, sometimes on campus, while he was dean. In the aftermath, the university faced numerous related expenses as it hired crisis managers and launched an investigation into the school’s handling of the scandal.

University officials attributed the decline in contributions to normal fluctuations in fundraising.

Two USC employees involved with fundraising told the LA Times that donors were affected by the scandal and felt the school’s moral compass didn’t fit their own anymore.

USC has transformed its fundraising efforts in recent years. It launched a $6 billion fundraising campaign in 2011 and surpassed its goal in 6 1/2 years, raising as much in that time as it had in the previous 6 1/2 decades combined, the school said.

Puliafito’s own reputation was built around his fundraising prowess, both at USC and Bascom Palmer Eye Institute.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023